Last Updated on October 10, 2024 by The Health Master
WHO Alert
In a recent announcement, the World Health Organization (WHO) has issued a global WHO alert regarding contaminated syrups and suspension medicines manufactured by Pharmix Laboratories in Pakistan.
This WHO alert, covering regions including the Americas, the Eastern Mediterranean, South-East Asia, and the Western Pacific, highlights the potential dangers posed by these products.
Identification and Origin
The WHO reports that the affected products, namely ALERGO Syrup, EMIDONE Suspension, MUCORID Syrup, ULCOFIN Suspension, and ZINCELL Syrup, were initially identified in the Maldives and Pakistan.
Subsequently, cases have been reported in Belize, Fiji, and the Lao People’s Democratic Republic.
Quality Control Issues
Samples of ALERGO syrup from five different batches underwent rigorous testing by the Maldives Food and Drug Authority (MFDA).
The results raised serious concerns, revealing unacceptable levels of diethylene glycol and ethylene glycol as contaminants.
Further laboratory tests by the Therapeutic Goods Administration of Australia confirmed contamination levels well above accepted limits.
Manufacturer’s Response and Regulatory Actions
Pharmix Laboratories, the manufacturer in question, underwent a thorough inspection by the Drug Regulatory Authority of Pakistan (DRAP).
The findings suggested the possibility of contaminants in other products and batches manufactured by Pharmix Laboratories.
As a precautionary measure, DRAP instructed Pharmix Laboratories to halt the production of all oral liquid dosage medicines.
Subsequently, on November 16, 2023, DRAP issued a recall alert for five different syrup medicines manufactured by Pharmix Laboratories.
Precautionary Measures by WHO
While no adverse effects have been reported to WHO thus far, the organization, out of an abundance of caution, recommends increased vigilance and testing for oral liquid dosage medicines produced by Pharmix Laboratories between December 2021 and December 2022.
WHO emphasizes that the substandard products mentioned in the alert are unsafe, especially for children, and may lead to serious injury or death.
Potential Health Risks and Toxic Effects
WHO warns that the usage of these contaminated products, particularly in children, can result in severe health issues.
Toxic effects may include abdominal pain, vomiting, diarrhea, inability to pass urine, headache, altered mental state, and acute kidney injury.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
FAQs:
- Q: How were the contaminated syrups initially identified?
- A: The Maldives Food and Drug Authority (MFDA) conducted routine screening using the thin layer chromatography (TLC) test for diethylene glycol and ethylene glycol.
- Q: Are there any reported adverse effects linked to the affected products?
- A: As of now, no adverse effects have been reported to the World Health Organization (WHO).
- Q: What actions have regulatory authorities taken against Pharmix Laboratories?
- A: The Drug Regulatory Authority of Pakistan (DRAP) instructed Pharmix Laboratories to stop production, and a recall alert was issued for the affected syrup medicines.
- Q: What time frame does WHO recommend increased vigilance for?
- A: WHO recommends increased vigilance and testing for oral liquid dosage medicines produced by Pharmix Laboratories between December 2021 and December 2022.
- Q: What are the potential toxic effects of using these contaminated products?
- A: Toxic effects may include abdominal pain, vomiting, diarrhea, altered mental state, and acute kidney injury, which can be fatal.
Drug Regulatory Authorities: Worldwide
Pakistan: New technology introduced for instant detection of spurious drugs
Pakistan allows import of Vital Medicines from India
German pharma major Bayer stops business in Pakistan: Report
Worst medicine crisis in Pakistan
Pharma Industry announced to stop producing medicines: Pakistan
USFDA approval granted for Smoking Cessation Drug
IPC Alert: About adverse reactions to Meftal Painkiller
USFDA Inspection at R&D Facility of Dr. Reddy’s Lab
The Game-Changing New Drug Law to be introduced in Parliament
USFDA Approval granted for Canagliflozin Tablets for Diabetes Treatment
Pharma Industry advocates Solutions for Licensing and Export Challenges
Drug recall: Antifungal Spray Powder Due to the Presence of Benzene
New Amendments to Section 32B of the Drugs and Cosmetics Act, 1940
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
